Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Kimia Biosciences Ltd (KIMIABL) is currently trading at 35.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Kimia Bio-sciences Limited, formerly known as Laurel Organics Limited, focuses on manufacturing bulk drugs and APIs at its plant in Gurgaon, Haryana. The company faced financial difficulties and was declared a sick unit during 1998-99, but later recovered and moved out of the BIFR purview by 2005. In 2018, Kimia Biosciences Limited underwent a reverse merger with its holding company, which was holding a majority equity stake. Kimia has maintained its strategic focus on pharmaceuticals, particularly in manufacturing and supplying APIs, strengthening its market position.
Over the past 52 weeks, Kimia Biosciences Ltd has traded between a low of ₹23.20 and a high of ₹86.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Kimia Biosciences Ltd has a market capitalization of approximately 169.62. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Kimia Biosciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 18.74 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 169.62 Cr, Kimia Biosciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Kimia Biosciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Kimia Biosciences Ltd is 18.74. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
CFO Appointment
Kimia Biosciences Ltd appointed Mr. Mani Jain as Chief Financial Officer and Key Managerial Personnel effective April 27, 2026; he is a Chartered Accountant with over 28 years’ experience and is not related to any director.
CFO Appointment
Board of Kimia Biosciences appointed Mr. Mani Jain as Chief Financial Officer and Key Managerial Personnel effective April 27, 2026; he is a Chartered Accountant with over 28 years' finance experience and is not related to any director.
Bearish
3
Neutral
6
Bullish
5
Bearish
16
Neutral
6
Bullish
24
Bearish
13
Neutral
0
Bullish
19
Kimia Bio-sciences Limited, formerly known as Laurel Organics Limited, focuses on manufacturing bulk drugs and APIs at its plant in Gurgaon, Haryana.
The company faced financial difficulties and was declared a sick unit during 1998-99, but later recovered and moved out of the BIFR purview by 2005.
In 2018, Kimia Biosciences Limited underwent a reverse merger with its holding company, which was holding a majority equity stake.
Kimia has maintained its strategic focus on pharmaceuticals, particularly in manufacturing and supplying APIs, strengthening its market position.
Pharmaceuticals & Biotechnology
Pharmaceuticals
168 Cr
High Risk
18.6
33.2
0.1
14.6
86.85
23.20
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
68.00 | 175 Cr | 8.11 | 1.51 | 0.00 | 12.08 | 12.32 | 15.43 | ||
37.89 | 170 Cr | 18.74 | 14.64 | 0.00 | 70.62 | 33.57 | 8.92 | ||
159.60 | 168 Cr | 36.25 | 3.00 | 0.00 | 8.67 | 10.26 | 3.81 | ||
153.00 | 162 Cr | -8.45 | 0.71 | 0.00 | -4.87 | -1.11 | -4.56 | ||
268.00 | 152 Cr | 88.18 | 3.53 | 0.00 | 4.47 | 7.31 | 1.55 | ||
411.25 | 150 Cr | 10.75 | 0.71 | 0.00 | 8.14 | 10.97 | 6.01 | ||
104.25 | 150 Cr | 12.18 | 1.08 | 0.70 | 8.89 | 11.28 | 7.21 | ||
| Median: 7 Co. | — | 153.00 | 162 Cr | 12.18 | 1.51 | 0.00 | 8.67 | 10.97 | 6.01 |
